Digestive Disease Week 2014
DDW Daily News
The newspaper is distributed in the convention center four times during
the conference. Each issue focuses on one of the four DDW member
societies, highlighting timely information and news about scheduled
events and scientific sessions.
DDW 2014 Issues:
Tuesday, May 6
With less invasive alternatives available, liver biopsy rarely needed Liver biopsy is becoming an endangered procedure.
NASH is an indication for liver transplant
Fatty liver disease is not end-stage liver disease and thus would not be an indication for liver transplantation, according to Kymberly D. Watt, MD, associate professor of medicine and medical director of liver transplantation at the Mayo Clinic and Foundation in Rochester, MN. The same can't be said for nonalcoholic steatohepatitis (NASH), however.
Read More
Despite effectiveness, colonoscopy faces increased competition
The data are clear: screening colonoscopy reduces colorectal cancer (CRC) morbidity and mortality. But payors are demanding higher quality at a lower price and new technologies offer tempting alternatives.
Read More
Joint symposium will examine quality indicators in GI surgery
Representatives from SSAT and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) will gather today for the annual Kelly and Carlos Pellegrini SSAT/SAGES Joint Luncheon Symposium, which is titled Quality Indicators — Defining It Before Someone Else Does It for Us! The symposium will examine quality indicators in gastrointestinal surgery.
Read More
Experts to summarize Best of DDW 2014
Representatives from each of the four participating DDW® societies will summarize the most important findings presented at this year's meeting during today's Best of DDW 2014 session. DDW Council Chair Lawrence S. Friedman, MD, AGAF, FASGE, and DDW Council Treasurer J. Sumner Bell, MD, AGAF, will moderate the session, a perennial favorite for meeting attendees.
Read More
Click here to view these and more articles on your mobile device.
Click here to view the complete Tuesday issue of DDW Daily News on your computer or tablet.
View On Tablet Or Computer
Monday, May 5
Sunday, May 4
Saturday, May 3
View On Mobile Device
Monday
Saturday
Sunday
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
Here we did a study regarding ‘Unequal distribution of liver fat warrants careful selection of biopsy site during donor assessment’ https://goo.gl/etdGHo
ReplyDelete